Founded in 2014, Tonghua Anrate Biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical enterprise focusing on the research and development of recombinant human albumin, with a total investment of 1.117 billion yuan and more than 500 employees. After years of hard research and development, Anrate has explored a mature recombinant human albumin manufacturing process, and has a number of world-leading patents such as methanol-free Pichia pastoris protein green production technology, overcoming technical problems such as recombinant protein impurity analysis and immunogenicity control, achieving a significant reduction in production costs, and breaking the risk of virus transmission in blood products through technological innovation. At present, Anrate has successfully obtained the approval of the Eurasian Economic Union-Ministry of Health of the Russian Federation for marketing in April 2024, becoming the world's first and only marketed recombinant human albumin injection product. Today, relying on the advantages of large tonnage production capacity, Anrate expands its product pipeline, continues to promote the development of the biopharmaceutical field, and is committed to providing professional solutions for the global health cause.
通化安睿特生物制药股份有限公司成立于2014年，是专注重组人白蛋白研发的高科技生物制药企业，总投资11.17亿元，员工500余人。经多年努力研发，安睿特探索出成熟的重组人白蛋白生产工艺，并拥有无甲醇毕赤酵母蛋白质绿色生产技术等多项专利，攻克重组蛋白杂质分析、免疫原性控制等技术难题，实现生产成本大幅降低，通过技术创新打破血源病毒传播风险。目前安睿特已于2024年4月成功获得欧亚经济联盟﹣俄罗斯联邦卫生部批准上市，成为全球首个，也是唯一一个上市的重组人白蛋白注射液产品。如今，安睿特依托大吨位产能优势拓展产品管线，持续推动生物制药领域发展，致力于为全球健康事业提供专业解决方案。
